Compounds > butyloxycarbonyl-leucyl-glycyl-arginine-4-nitroanilide
Page last updated: 2024-11-07

butyloxycarbonyl-leucyl-glycyl-arginine-4-nitroanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

butyloxycarbonyl-leucyl-glycyl-arginine-4-nitroanilide: synthetic chromogenic substrate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129286
MeSH IDM0109291

Synonyms (7)

Synonym
tert-butyl n-[(2s)-1-[[2-[[(2s)-5-(diaminomethylideneamino)-2-(4-nitroanilino)pentanoyl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
n-tert-butoxycarbonyl-l-leucyl-l-glycyl-l-arginine-p-nitroaniline
butyloxycarbonyl-leucyl-glycyl-arginine-4-nitroanilide
l-argininamide, n-((1,1-dimethylethoxy)carbonyl)-l-leucylglycyl-n-(4-nitrophenyl)-
butyloxycarbonyl-leucyl-glycyl-arginyl-para-nitroanilide
DTXSID70987738
2-{[tert-butoxy(hydroxy)methylidene]amino}-n-(2-hydroxy-2-{[n~2~-(4-nitrophenyl)arginyl]imino}ethyl)-4-methylpentanimidic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-nitroaniline
[no description available]		2.0710nitroanilinebacterial xenobiotic metabolite
silver chloride
[no description available]		2.0710inorganic chloride;
silver salt
ConditionIndicatedRelationship StrengthStudiesTrials
Brain Inflammation
[description not available]		01.9810
Pachymeningitis
[description not available]		01.9810
Enteric Fever
[description not available]		01.9810
Encephalitis
Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.		01.9810
Meningitis
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)		01.9810
Typhoid Fever
An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.		01.9810
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		01.9810